The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Research And Treatment
Bardia, Aditya A; Mayer, Ingrid I; Winer, Eric E; Linden, Hannah M HM; Ma, Cynthia X CX; Parker, Barbara A BA; Bellet, Meritxell M; Arteaga, Carlos L CL; Cheeti, Sravanthi S; Gates, Mary M; Chang, Ching-Wei CW; Fredrickson, Jill J; Spoerke, Jill M JM; Moore, Heather M HM; Giltnane, Jennifer J; Friedman, Lori S LS; Chow Maneval, Edna E; Chan, Iris I; Jhaveri, Komal K
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Therapeutic Advances In Medical Oncology
Lloyd, Maxwell R MR; Wander, Seth A SA; Hamilton, Erika E; Razavi, Pedram P; Bardia, Aditya A
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.
Breast Cancer Research : Bcr
Jager, Agnes A; de Vries, Elisabeth G E EGE; der Houven van Oordt, C Willemien Menke-van CWM; Neven, Patrick P; Venema, Clasina M CM; Glaudemans, Andor W J M AWJM; Wang, Yamei Y; Bagley, Rebecca G RG; Conlan, Maureen G MG; Aftimos, Philippe P
Quantitative Evaluation of the Transcriptional Activity of Steroid Hormone Receptor Mutants and Variants Using a Single Vector With Two Reporters and a Receptor Expression Cassette.
Frontiers In Endocrinology
Ji, Huimin H; Li, Ying Y; Liu, Zhao Z; Tang, Min M; Zou, Lihui L; Su, Fei F; Zhang, Yaqun Y; Zhang, Junhua J; Li, Hexin H; Li, Lin L; Ai, Bin B; Ma, Jie J; Wang, Lunan L; Liu, Ming M; Xiao, Fei F
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Cancers
Froyen, Guy G; Le Mercier, Marie M; Lierman, Els E; Vandepoele, Karl K; Nollet, Friedel F; Boone, Elke E; Van der Meulen, Joni J; Jacobs, Koen K; Lambin, Suzan S; Vander Borght, Sara S; Van Valckenborgh, Els E; Antoniou, Aline A; Hébrant, Aline A
Integrative omics analyses broaden treatment targets in human cancer.
Genome Medicine
Sengupta, Sohini S; Sun, Sam Q SQ; Huang, Kuan-Lin KL; Oh, Clara C; Bailey, Matthew H MH; Varghese, Rajees R; Wyczalkowski, Matthew A MA; Ning, Jie J; Tripathi, Piyush P; McMichael, Joshua F JF; Johnson, Kimberly J KJ; Kandoth, Cyriac C; Welch, John J; Ma, Cynthia C; Wendl, Michael C MC; Payne, Samuel H SH; Fenyö, David D; Townsend, Reid R RR; Dipersio, John F JF; Chen, Feng F; Ding, Li L
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Nature Communications
Spoerke, Jill M JM; Gendreau, Steven S; Walter, Kimberly K; Qiu, Jiaheng J; Wilson, Timothy R TR; Savage, Heidi H; Aimi, Junko J; Derynck, Mika K MK; Chen, Meng M; Chan, Iris T IT; Amler, Lukas C LC; Hampton, Garret M GM; Johnston, Stephen S; Krop, Ian I; Schmid, Peter P; Lackner, Mark R MR
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Nature Genetics
Toy, Weiyi W; Shen, Yang Y; Won, Helen H; Green, Bradley B; Sakr, Rita A RA; Will, Marie M; Li, Zhiqiang Z; Gala, Kinisha K; Fanning, Sean S; King, Tari A TA; Hudis, Clifford C; Chen, David D; Taran, Tetiana T; Hortobagyi, Gabriel G; Greene, Geoffrey G; Berger, Michael M; Baselga, José J; Chandarlapaty, Sarat S